A Review Article on Selective Serotonin Reuptake Inhibitors (SSRIS)

  • Devi Meena College of Pharmacy, Roorkee Uttarakhand, India
  • Subhash Subhash Chand College of Pharmacy, Roorkee Uttarakhand, India
  • Deovrat Kumar College of Pharmacy, Roorkee Uttarakhand, India

Abstract

Depression, tension and mental health have been ignored as a serious issue since ages. Depression can be fatal or life-threatening, if not treated to this problem. Antidepressants are also regularly used to treat many other conditions, such as social phobia, fibromyalgia, panic disorder, anxiety/anxiety depression, PTSD, OCD, PMDD, and menopause. The major antidepressant used in the study followed oral prescribing trends. A “serious adverse reaction means an adverse reaction which is fatal, life-threatening, disabling, incapacitating, or which results in or prolongs hospitalization.” Material method collect from Google, Wikipedia, Elsevier, PubMed, Google scholar, Sci-Hub etc. This is a meta-analysis study. Fluoxetine have the longest half-life, but Fluvoxamine have short half-life. SSRIs increase the serum concentrations of the latter two drugs, potentiating their effects and increasing the risk of toxicity. Fluoxetine and Paroxetine specifically, are known to cause a 5-fold increase in serum TCA concentration upon co-administration. By in the addition of combination therapy SSRIs associated many types of adverse drug reaction and some time it can cause serotonin syndrome also.


 

Keywords: Depression, Antidepressants, Adverse drug reaction, Serotonin syndrome, Combination therapy.

Downloads

Download data is not yet available.

Author Biographies

Devi Meena, College of Pharmacy, Roorkee Uttarakhand, India

College of Pharmacy Roorkee, Uttarakhand, India

Subhash Subhash Chand, College of Pharmacy, Roorkee Uttarakhand, India

College of Pharmacy, Roorkee Uttarakhand, India

Deovrat Kumar, College of Pharmacy, Roorkee Uttarakhand, India

College of Pharmacy, Roorkee Uttarakhand, India

References

1. Depression and other common mental disorders: global health estimates. Geneva: World Health Organization; 2017 (http://apps.who.int/iris/handle/10665/254610, accessed 25 March 2017).
2. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). American Psychiatric Association. 2013.
3. Volkomer MM. Adolescent Mindfulness Interventions: A Meta-Analysis of the Effects on Anxiety and Depression.
4. Lederman S, Harris H, inventors; Tonix Pharma Holdings Limited, assignee. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine. United States patent US 9,474,728. 2016; 25.
5. Slaton RM, Champion MN, Palmore KB. A review of paroxetine for the treatment of vasomotor symptoms. Journal of pharmacy practice. 2015; 28(3):266-74.
6. Siepmann T, Penzlin AI, Kepplinger J, Illigens BM, Weidner K, Reichmann H, Barlinn K. Selective serotonin reuptake inhibitors to improve outcome in acute ischemic stroke: possible mechanisms and clinical evidence. Brain and behavior. 2015; 5(10):e00373.
7. Rossiter D, editor. South African medicines formulary. Health and Medical Publishing Group; 2016.
8. Albert PR, Vahid-Ansari F, Luckhart C. Serotonin-prefrontal cortical circuitry in anxiety and depression phenotypes: pivotal role of pre-and post-synaptic 5-HT1A receptor expression. Frontiers in behavioral neuroscience. 2014 Jun 6;8:199.
9. Daubert EA, Condron BG. Serotonin: a regulator of neuronal morphology and circuitry. Trends in neurosciences. 2010 Sep 1; 33(9):424-34.
10. Sarkar S, Harihar S, Patra BN. Sexual dysfunction due to SSRI antidepressants: How to manage?. Apollo Medicine. 2016; 13(2):97-101.
11. Chigome AK, Matsangaise MM, Chukwu BO, Matlala M, Sibanda M, Meyer JC. Review of selective serotonin reuptake inhibitors. SA Pharmaceutical Journal. 2017; 84(6):52-9.
12. Woytowish MR, Maynor LM. Clinical relevance of linezolid-associated serotonin toxicity. Annals of Pharmacotherapy. 2013; 47(3):388-97.
13. Ducasse D, Boyer L, Michel P, Loundou A, Macgregor A, Micoulaud-Franchi JA, Courtet P, Abbar M, Leboyer M, Fond G. D2 and D3 dopamine receptor affinity predicts effectiveness of antipsychotic drugs in obsessive-compulsive disorders: a metaregression analysis. Psychopharmacology. 2014; 231(18):3765-70.
14. Manolopoulos VG, Ragia G, Alevizopoulos G. Pharmacokinetic interactions of selective serotonin reuptake inhibitors with other commonly prescribed drugs in the era of pharmacogenomics. Drug metabolism and drug interactions. 2012; 27(1):19-31.
15. Bérard A, Zhao JP, Sheehy O. Sertraline use during pregnancy and the risk of major malformations. American journal of obstetrics and gynecology. 2015; 212(6):795-e1.
16. Kaplan YC, Keskin-Arslan E, Acar S, Sozmen K. Prenatal selective serotonin reuptake inhibitor use and the risk of autism spectrum disorder in children: A systematic review and meta-analysis. Reproductive Toxicology. 2016; 66:31-43.
17. Wilson E, Lader M. A review of the management of antidepressant discontinuation symptoms. Therapeutic advances in psychopharmacology. 2015; 5(6):357-68.
Statistics
33 Views | 39 Downloads
How to Cite
Meena, D., Subhash Chand, S., & Kumar, D. (2019). A Review Article on Selective Serotonin Reuptake Inhibitors (SSRIS). Asian Journal of Pharmaceutical Research and Development, 7(6), 72-75. https://doi.org/https://doi.org/10.22270/ajprd.v7i6.592